Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is one of the stocks on Jim Cramer’s radar recently. During the lightning round, ...

We came across a bullish thesis on Catalyst Pharmaceuticals, Inc. on BioEquity Watch’s Substack. In this article, we will ...

Catalyst Pharmaceuticals recently announced that it was ranked 11th on Forbes’ 2026 list of America’s Most Successful ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The popular research ...

CORAL GABLES, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel ...

Shares of Catalyst Pharmaceuticals Inc. CPRX slid 3.75% to $22.35 Tuesday, on what proved to be an all-around dismal trading ...

Achieved Record Q2 2025 Total Revenues of $146.6 Million, an Increase of 19.4% YoY, Marking Another Quarter of Consecutive Growth Reported Record First Half 2025 Total Revenues of $288.0 Million, an ...

The webcast will be available under the Investors section on the Company's website, www.catalystpharma.com, and a replay will be available for at least 30 days. About Catalyst Pharmaceuticals, Inc.

CORAL GABLES, Fla., July 22, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, ...

Catalyst Pharmaceuticals will release Q2 2025 financial results on August 6, 2025, followed by a conference call on August 7. Catalyst Pharmaceuticals, Inc. announced its schedule for releasing its ...

Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX), is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing ...